VLADIMIR PUTIN
ARCHIVE OF THE OFFICIAL SITE
OF THE 2008-2012 PRIME MINISTER
OF THE RUSSIAN FEDERATION
VLADIMIR PUTIN
ARCHIVE OF THE OFFICIAL SITE
OF THE 2008-2012 PRIME MINISTER
OF THE RUSSIAN FEDERATION
VLADIMIR PUTIN
The Yaroslavl Region is a priority region for building a modern pharmaceutical industry. Several major investment projects in the pharmaceutical industry are currently being carried out in the region.
Nycomed pharmaceuticals plant (Novoselki Industrial Park, Yaroslavl)
Construction on the production facility will begin in the summer of 2010, and it is expected to begin producing pharmaceutical products in finished dosage form in 2013 or 2014. The production facility will meet both Russian pharmaceutical product standards and international good manufacturing practices (GMPs), as well as the latest standards for energy efficiency, occupational safety and environmental friendliness.
The company will invest between 75 and 80 million euros in this production facility over the next five years. At the initial stage it will employ about 150 workers.
The facility will specialise in the innovative production of sterile solutions (in ampoules and vials) and medicines in capsule dosage form (pills). It will also produce well-known drugs in the Russian market such as Kardiomagnil, Aktovegin, Calcium DZ-Nycomed and Varfarin.
R-Pharm pharmaceuticals plant (Yaroslavl)
The R-Pharm project has received between 1.5 and two billion roubles in investment and will create up to 200 jobs. Construction is due to be completed in late 2010 or early 2011.
The production facility will manufacture pharmaceutical products in injectable dosage form intended to be used in hospitals to treat diseases classified as socially significant, primarily bacterial, viral and fungal infections, diabetes, cancer, blood diseases, rheumatism and immunological diseases. Agreements have been signed with several major pharmaceutical companies for the licensed production of patented drugs with well-known international brand names. The production facility will also produce generic drugs.
NTpharma pharmaceutical plant (Pereslavl-Zalessky)
The NTpharma project has a total budget of 1.5 billion roubles and will create 150 new jobs. The facility will begin producing nano-vaccines and preparation based on biological extracts in 2012, and production is expected to reach 60 million ampoules a year. The project has also received support from the state-owned company RosNano.
The project also entails the development of two vaccines against human and avian influenza; three pharmaceutical products based on biological extracts to treat cancer, stimulate the immune system and work to amplify the effects of antibacterial and antiviral drugs; and drugs to treat lower-limb ischemia and amyotrophic lateral sclerosis. The research is being coordinated by the Gamaleya Research Institute of the Russian Academy of Medical Sciences, with participation from the Russian Academy of Medical Science's Flu Research Institute, the Russian Academy of Science's Molecular Genetics Institute, the Russian Academy of Medical Science's Neurology Research Centre, the Russian Ministry of Health's Herzen Oncology Research Institute in Moscow, the Russian Medical Academy of Science's Petrovsky Russian Surgery Centre, as well as many other research institutions.
Pharmoslavl
A joint project by R-Pharm and the KhimRar high-tech research centre, Pharmoslavl will be the first modern production facility in Russia to produce active pharmaceutical ingredients for drugs. The project is expected to attract about two billion roubles in investment and be completed between 2010 and 2014.
By 2014, the production facility is expected to manufacture:
Other projects
Leading Russian skin-care-product manufacturer Bentus Laboratories has plans to build a production facility for antiseptic agents in Pereslavl-Zalessky.
Firma Vitafarma will soon move its production of herpes vaccines and new pharmaceutical products that utilise bacteria from from Moscow to Pereslavl-Zalessky.
Negotiations are underway with leading Russian and foreign companies to localise pharmaceutical production in the Yaroslavl Region and launch licensed production at existing facilities.
The government of the Yaroslavl Region is currently working to create a multi-tiered instructional system to educate personnel for the region's modern pharmaceutical industry.
